CD36 deficiency induced by antiretroviral therapy

AIDS

Volumn 16, Issue 3, 2002, Pages 353-358

  Serghides, Lena ^a   Nathoo, Salima ^a   Walmsley, Sharon ^a   Kain, Kevin C ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Antiretroviral therapy; Fluorescence assisted cell sorting; HIV; Lipodystrophy; Protease inhibitors; Receptor; Ritonavir

Indexed keywords

ANTIRETROVIRUS AGENT; CD36 ANTIGEN; LOPINAVIR; NELFINAVIR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROTEINASE INHIBITOR; ZIDOVUDINE;

ARTICLE; CELL SELECTION; CLINICAL ARTICLE; COHORT ANALYSIS; FLOW CYTOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LIPODYSTROPHY; MONOCYTE; NONHUMAN; PRIORITY JOURNAL;

ANTI-HIV AGENTS; ANTIGENS, CD36; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CELL LINE; COHORT STUDIES; HIV INFECTIONS; HIV-1; HUMANS; INSULIN RESISTANCE; LIPODYSTROPHY; MONOCYTES; PROSPECTIVE STUDIES; RITONAVIR; ZIDOVUDINE;

EID: 0037083729     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200202150-00006     Document Type: Article

References (42)

1. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
2. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
3. Changing incidence of AIDS-defining illness in the era of antiretroviral combination therapy
4. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance
5. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA panel
6. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors
7. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients
8. Diagnosis, prediction, and natural history of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidemia and diabetes mellitus: A cohort study
9. Adverse effects of antiretroviral therapy
10. Coronary artery disease and human immunodeficiency virus infection
11. Severe premature coronary artery disease with protease inhibitors
12. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infraction
13. Triglyceride concentration and ischemic heart disease: An eight-year follow-up in the Copenhagen male study
14. HIV protease inhibitors block human preadipocyte differentiation, but not via PPARγ/ RXR heterodimer
15. Inhibition of adipocyte differentiation by HIV protease inhibitors
16. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
17. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL
18. Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation: Homology with human CD36
19. Defective uptake and utilization of long chain fatty acids in muscle and adipose tissues of CD36 knockout mice
20. Identification of CD36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats
21. CD36 and molecular mechanisms of insulin resistance in the stroke-prone spontaneously hypertensive rat
22. Transgenic rescue of defective Cd36 ameliorates insulin resistance in spontaneously hypertensive rats
23. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism
24. Muscle-specific over-expression of FAT/CD36 enhances fatty acid oxidation by contracting muscle, reduces plasma triglycerides and fatty acids, and increases plasma glucose and insulin
25. CD36 deficiency associated with insulin resistance
26. CD36, insulin resistance, and coronary heart disease
27. Non-opsonic monocyte phagocytosis of Plasmodium falciparum-parasitized erythrocytes: A role for CD36 in malaria clearance
28. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice
29. Scavenging new insights into atherogenesis
30. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice
31. Peroxisome proliferator-activated receptor gamma ligands and atherosclerosis: Ending the heartache
32. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway
33. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake
34. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ
35. Human CD36 deficiency is associated with elevation in low density lipoprotein-cholesterol
36. Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-deficient subjects
37. Is CD36 deficiency an etiology of hereditary hypertrophic cardiomyopathy?
38. Different patterns of 1231-BMIPP myocardial accumulation in patients with type I and II CD36 deficiency
39. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
40. Leptin regulation of peroxisome proliferator-activated receptor-gamma, tumor necrosis factor, and uncoupling protein-expression in adipose tissues
41. Differentiation-dependent expression of the brown adipocyte uncoupling protein gene: Regulation by peroxisome proliferator-activated receptor-gamma
42. Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus